FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome. (Q52603828)
Jump to navigation
Jump to search
scientific article published on 5 April 2018
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome. |
scientific article published on 5 April 2018 |
Statements
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome (English)
Robert Q Le
Liang Li
Weishi Yuan
Stacy S Shord
Lei Nie
Bahru A Habtemariam
Donna Przepiorka
Ann T Farrell
Richard Pazdur
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference